{"organizations": ["GlaxoSmithKline"], "uuid": "7dc26008264ca26d2ea62ca4e15858423384aa06", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.finance.yahoo.com", "main_image": "https://s1.yimg.com/bt/api/res/1.2/M7vS95b2fvSzHFeFStPk0A--/YXBwaWQ9eW5ld3NfbGVnbztxPTc1O3c9NjAw/http://l.yimg.com/os/mit/media/m/social/images/social_default_logo-1481777.png", "site_section": "https://uk.finance.yahoo.com/news/provider-sharecast/?format=rss", "section_title": "Finance News | Sharecast - Yahoo! UK & Ireland Finance", "url": "https://uk.finance.yahoo.com/news/glaxosmithkline-file-application-copd-drug-084800049.html", "country": "GB", "title": "GlaxoSmithKline to file application for COPD drug in Japan", "performance_score": 0, "site": "yahoo.com", "participants_count": 0, "title_full": "GlaxoSmithKline to file application for COPD drug in Japan", "spam_score": 0.0, "site_type": "news", "published": "2015-09-24T11:48:00.000+03:00", "replies_count": 0, "uuid": "7dc26008264ca26d2ea62ca4e15858423384aa06"}, "author": "", "url": "https://uk.finance.yahoo.com/news/glaxosmithkline-file-application-copd-drug-084800049.html", "ord_in_thread": 0, "title": "GlaxoSmithKline to file application for COPD drug in Japan", "locations": ["Japan"], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Tip : Use comma (,) to separate multiple quotes. Learn more... \nThu, Sep 24, 2015, 09:59 BST - UK Markets close in 6 hrs 31 mins GlaxoSmithKline to file application for COPD drug in Japan By Michele Maatouk | Sharecast – 11 minutes ago 19.73 +0.63 \nLONDON (ShareCast) - (ShareCast News) - GlaxoSmithKline (Other OTC: GLAXF - news ) and Theravance (NasdaqGS: THRX - news ) intend to file a supplemental new drug application with the Japanese regulatory authority in the first quarter of 2016 for Relvar Ellipta, which is used for the treatment of chronic obstructive pulmonary disease. The pharmaceuticals company said the decision follows results from a phase III efficacy and safety study involving 1,620 patients, 370 of whom were from Japan, which showed that patients who received the Relvar Ellipta combination achieved a statistically significant improvement in lung function. \nGlaxo said full results from the study will be the subject of a future publication or presentation. \nAt 0830 BST, shares in Glaxo were down 0.5% at 1,268.07p. Tax cuts, pensions, childcare, online accounts and beer duty, here's … Related Stock Articles What’s The Number One Difference Between GlaxoSmithKline plc And AstraZeneca plc? - Fool.co.uk Follow the quotes you care about most. Access timely news and investment updates to stay on top of the market. … More » Yahoo UK & Ireland Finance Terms \nQuotes are real-time for NASDAQ, NYSE, and NYSEAmex when available. See also delay times for other exchanges . Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page . Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided \"as is\" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein. \nFundamental company data provided by Capital IQ . Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI) . International historical chart data and daily updates provided by Morningstar, Inc . Yahoo! - News Network", "external_links": [], "published": "2015-09-24T11:48:00.000+03:00", "crawled": "2015-09-24T12:01:44.964+03:00", "highlightTitle": ""}